ILCA 2019 - 13th Annual Conference of the International Liver Cancer Association
Sep 20 - Sep 22, 2019 | ChicagoILUS
LARVOL is not affiliated with 13th Annual Conference of the International Liver Cancer Association and all trademarks, logos, and brand names are property of their respective owners
Showing 31 abstracts linked to Trials
Results of a Phase 3 Study of Pembrolizumab Versus Best Supportive Care for Second-Line Therapy in Advanced Hepatocellular Carcinoma: KEYNOTE-240
Multicentric Prospective Study Of Validation Of Angiogenesis-Related Gene Polymorphisms In Hepatocellular Carcinoma Patients Treated With Sorafenib: Final Results Of Innovate Study
Alpha-fetoprotein (AFP) response and efficacy outcomes in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)
First-in-human, first-in-class phase I trial of MTL-CEBPA, a RNA oligonucleotide Targeting the Transcription Factor C/EBP-α, Given as a Single Agent or in Combination with Sorafenib, in Patients with Advanced Hepatocellular Cancer (HCC)
CHECKMATE 040: HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (AHCC) AND CHILD-PUGH B STATUS TREATED WITH NIVOLUMAB (NIVO)
Phase Ib Study Results: Safety and Efficacy of Atezolizumab + Bevacizumab Versus Atezolizumab in Patients with Previously Untreated, Unresectable or Advanced
Safety Profile of Nivolumab (NIVO) Plus Ipilimumab (IPI) Combination Therapy in Patients (pts) With Advanced Hepatocellular Carcinoma (HCC) in the CheckMate 040 Study
Randomized, Open-Label, Perioperative Phase II Study Evaluating Nivolumab Alone or Nivolumab Plus Ipilimumab in Patients with Resectable HCC
A PHASE 3; RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY OF TRANSARTERIAL CHEMOEMBOLIZATION COMBINED WITH DURVALUMAB OR DURVALUMAB PLUS BEVACIZUMAB THERAPY IN PATIENTS WITH LOCOREGIONAL HEPATOCELLULAR CARCINOMA (HCC): EMERALD-1
RETROSPECTIVE, EXPLORATORY ANALYSIS OF THE OPTIMIS STUDY IN A SUBGROUP OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH TRANSARTERIAL CHEMOEMBOLIZATION (TACE) WHO RECEIVED SORAFENIB
The Safety and Efficacy of Namodenoson in the Second Line Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients with Underlying Child-Pugh B (CPB) Liver Cirrhosis: A Phase 2; Randomized, Double-Blind, Placebo-Controlled
ALPHA-FETOPROTEIN (AFP) RESPONSE AND OUTCOMES IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH REGORAFENIB OR PLACEBO IN THE PHASE 3 RESORCE TRIAL
MATCHING-ADJUSTED INDIRECT COMPARISON OF CABOZANTINIB VERSUS REGORAFENIB IN ADVANCED HEPATOCELLULAR CARCINOMA
SAFETY AND EFFICACY OF 12 MG/D LENVATINIB (LEN) IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC) AND BODYWEIGHT (BW) >80 KG IN REFLECT
MULTICENTER PHASE II STUDY OF STEREOTACTIC ABLATIVE RADIOTHERAPY FOR HEPATOCELLULAR CARCINOMA ≤ 5 CM (KROG 12-02)